Literature DB >> 21366534

Pyrimidine salvage pathway in Mycobacterium tuberculosis.

A D Villela1, Z A Sánchez-Quitian, R G Ducati, D S Santos, L A Basso.   

Abstract

The causative agent of tuberculosis (TB), Mycobacterium tuberculosis, infects one-third of the world population. TB remains the leading cause of mortality due to a single bacterial pathogen. The worldwide increase in incidence of M. tuberculosis has been attributed to the high proliferation rates of multi and extensively drug-resistant strains, and to co-infection with the human immunodeficiency virus. There is thus a continuous requirement for studies on mycobacterial metabolism to identify promising targets for the development of new agents to combat TB. Singular characteristics of this pathogen, such as functional and structural features of enzymes involved in fundamental metabolic pathways, can be evaluated to identify possible targets for drug development. Enzymes involved in the pyrimidine salvage pathway might be attractive targets for rational drug design against TB, since this pathway is vital for all bacterial cells, and is composed of enzymes considerably different from those present in humans. Moreover, the enzymes of the pyrimidine salvage pathway might have an important role in the mycobacterial latent state, since M. tuberculosis has to recycle bases and/or nucleosides to survive in the hostile environment imposed by the host. The present review describes the enzymes of M. tuberculosis pyrimidine salvage pathway as attractive targets for the development of new antimycobacterial agents. Enzyme functional and structural data have been included to provide a broader knowledge on which to base the search for compounds with selective biological activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21366534     DOI: 10.2174/092986711795029555

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  14 in total

1.  Increasing the structural coverage of tuberculosis drug targets.

Authors:  Loren Baugh; Isabelle Phan; Darren W Begley; Matthew C Clifton; Brianna Armour; David M Dranow; Brandy M Taylor; Marvin M Muruthi; Jan Abendroth; James W Fairman; David Fox; Shellie H Dieterich; Bart L Staker; Anna S Gardberg; Ryan Choi; Stephen N Hewitt; Alberto J Napuli; Janette Myers; Lynn K Barrett; Yang Zhang; Micah Ferrell; Elizabeth Mundt; Katie Thompkins; Ngoc Tran; Sally Lyons-Abbott; Ariel Abramov; Aarthi Sekar; Dmitri Serbzhinskiy; Don Lorimer; Garry W Buchko; Robin Stacy; Lance J Stewart; Thomas E Edwards; Wesley C Van Voorhis; Peter J Myler
Journal:  Tuberculosis (Edinb)       Date:  2014-12-19       Impact factor: 3.131

2.  Modeling phenotypic metabolic adaptations of Mycobacterium tuberculosis H37Rv under hypoxia.

Authors:  Xin Fang; Anders Wallqvist; Jaques Reifman
Journal:  PLoS Comput Biol       Date:  2012-09-13       Impact factor: 4.475

3.  Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG.

Authors:  Giorgia Mori; Laurent R Chiarelli; Marta Esposito; Vadim Makarov; Marco Bellinzoni; Ruben C Hartkoorn; Giulia Degiacomi; Francesca Boldrin; Sean Ekins; Ana Luisa de Jesus Lopes Ribeiro; Leonardo B Marino; Ivana Centárová; Zuzana Svetlíková; Jaroslav Blaško; Elena Kazakova; Alexander Lepioshkin; Nathalie Barilone; Giuseppe Zanoni; Alessio Porta; Marco Fondi; Renato Fani; Alain R Baulard; Katarína Mikušová; Pedro M Alzari; Riccardo Manganelli; Luiz Pedro S de Carvalho; Giovanna Riccardi; Stewart T Cole; Maria Rosalia Pasca
Journal:  Chem Biol       Date:  2015-06-18

4.  UPRT, a suicide-gene therapy candidate in higher eukaryotes, is required for Drosophila larval growth and normal adult lifespan.

Authors:  Arpan C Ghosh; MaryJane Shimell; Emma R Leof; Macy J Haley; Michael B O'Connor
Journal:  Sci Rep       Date:  2015-08-14       Impact factor: 4.379

5.  RepTB: a gene ontology based drug repurposing approach for tuberculosis.

Authors:  Anurag Passi; Neeraj Kumar Rajput; David J Wild; Anshu Bhardwaj
Journal:  J Cheminform       Date:  2018-05-21       Impact factor: 5.514

6.  Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.

Authors:  Kirsten E Knoll; Zander Lindeque; Adetomiwa A Adeniji; Carel B Oosthuizen; Namrita Lall; Du Toit Loots
Journal:  Microorganisms       Date:  2021-05-28

7.  Biochemical characterization of uracil phosphoribosyltransferase from Mycobacterium tuberculosis.

Authors:  Anne Drumond Villela; Rodrigo Gay Ducati; Leonardo Astolfi Rosado; Carlos Junior Bloch; Maura Vianna Prates; Danieli Cristina Gonçalves; Carlos Henrique Inacio Ramos; Luiz Augusto Basso; Diogenes Santiago Santos
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

8.  Discovery of anthelmintic drug targets and drugs using chokepoints in nematode metabolic pathways.

Authors:  Christina M Taylor; Qi Wang; Bruce A Rosa; Stanley Ching-Cheng Huang; Kerrie Powell; Tim Schedl; Edward J Pearce; Sahar Abubucker; Makedonka Mitreva
Journal:  PLoS Pathog       Date:  2013-08-01       Impact factor: 6.823

9.  Decoding the similarities and differences among mycobacterial species.

Authors:  Sony Malhotra; Sundeep Chaitanya Vedithi; Tom L Blundell
Journal:  PLoS Negl Trop Dis       Date:  2017-08-30

10.  Characterisation of iunH gene knockout strain from Mycobacterium tuberculosis.

Authors:  Anne Drumond Villela; Valnês da Silva Rodrigues; Antônio Frederico Michel Pinto; Priscila Lamb Wink; Zilpa Adriana Sánchez-Quitian; Guilherme Oliveira Petersen; Maria Martha Campos; Luiz Augusto Basso; Diógenes Santiago Santos
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-03       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.